Lamivudine resistance in immunocompetent chronic hepatitis B - Incidence and patterns

被引：229

作者：

Honkoop, P

Niesters, HGM

deMan, RAM

Osterhaus, ADME

Schalm, SW

机构：

[1] ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT INTERNAL MED 2 CA 326,SECT HEPATOL,NL-3015 GD ROTTERDAM,NETHERLANDS

[2] ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT VIROL,NL-3015 GD ROTTERDAM,NETHERLANDS

来源：

JOURNAL OF HEPATOLOGY | 1997年 / 26卷 / 06期

关键词：

antiviral treatment; lamivudine; nucleoside analogues; viral resistance; virus hepatitis B; YMDD motif;

D O I：

10.1016/S0168-8278(97)80476-X

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Lamivudine is a non-toxic, potent inhibitor of hepatitis B virus replication. Recently, hepatitis B virus resistance to lamivudine has been described in patients using immunosuppressive drugs after liver transplantation. Methods: From our cohort of 81 consecutive patients treated with lamivudine, me selected all immunocompetent patients who received lamivudine monotherapy for a period over 26 weeks (n=14). Results: Lamivudine resistance with the characteristic mutation in the YMDD motif was observed in four patients (actuarial cumulative incidence: 39%). Two patterns of viral resistance were observed: incomplete response (n=2) and viral breakthrough (n=2). Conclusions: The observed high frequency of lamivudine resistance may have implications for the concept of long-term virus-suppressive therapy of chronic hepatitis B by lamivudine monotherapy.

引用

页码：1393 / 1395

页数：3

共 10 条

[1] HIGH-LEVEL RESISTANCE TO (-) ENANTIOMERIC 2'-DEOXY-3'-THIACYTIDINE IN-VITRO IS DUE TO ONE AMINO-ACID SUBSTITUTION IN THE CATALYTIC SITE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE [J].

BOUCHER, CAB ;

CAMMACK, N ;

SCHIPPER, P ;

SCHUURMAN, R ;

ROUSE, P ;

WAINBERG, MA ;

CAMERON, JM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) :2231-2234

[2]

De Man R. A., 1995, Journal of Hepatology, V23, P96

[3]

DEMAN RA, 1993, GUT, V34, pS5

[4] A PRELIMINARY TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B INFECTION [J].

DIENSTAG, JL ;

PERRILLO, RP ;

SCHIFF, ER ;

BARTHOLOMEW, M ;

VICARY, C ;

RUBIN, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1657-1661

[5] INHIBITION OF THE REPLICATION OF HEPATITIS-B VIRUS INVITRO BY 2',3'-DIDEOXY-3'-THIACYTIDINE AND RELATED ANALOGS [J].

DOONG, SL ;

TSAI, CH ;

SCHINAZI, RF ;

LIOTTA, DC ;

CHENG, YC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8495-8499

[6]

Larder BA, 1995, J ACQ IMMUN DEF SYND, V10, pS28

[7] Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine [J].

Ling, R ;

Mutimer, D ;

Ahmed, N ;

Boxall, EH ;

Elias, E ;

Dusheiko, GM ;

Harrison, TJ .

HEPATOLOGY, 1996, 24 (03) :711-713

[8]

Nevens F., 1995, Journal of Hepatology, V23, P91

[9] ACTIVITIES OF THE 4 OPTICAL ISOMERS OF 2',3'-DIDEOXY-3'-THIACYTIDINE (BCH-189) AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN HUMAN-LYMPHOCYTES [J].

SCHINAZI, RF ;

CHU, CK ;

PECK, A ;

MCMILLAN, A ;

MATHIS, R ;

CANNON, D ;

JEONG, LS ;

BEACH, JW ;

CHOI, WB ;

YEOLA, S ;

LIOTTA, DC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :672-676

[10] Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo [J].

Tipples, GA ;

Ma, MM ;

Fischer, KP ;

Bain, VG ;

Kneteman, NM ;

Tyrrell, DLJ .

HEPATOLOGY, 1996, 24 (03) :714-717

← 1 →